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tensive regimen was continued. Within 3 months from the initia-
tion of antihypertensive treatment, her blood pressure fell to
108/60 mm Hg, the GFR dropped from 91 to 69 mL/min, and
the albuminuria declined to 423 g/min (609 m/24 h). During
the following 18 years, GFR measured twice yearly ranged
between 50 and 70 mL/min; at the end of follow-up 2 years
ago, the value was 61 mL/min, giving a sustained rate of decline
in GFR during the total observation period of 0.4 mL/min/
year. With few exceptions, albuminuria stayed below 500 g/
min (720 mg/24 h), and the mean blood pressure during the
whole treatment period was 125/77 mm Hg. Glycosylated he-
moglobin (HbA1c) ranged between 7.7% and 10.3%, with a
mean of 9.0% during the observation period. Three years ago,
because of a progressive lack of hypoglycemic awareness, she
experienced several episodes of severe hypoglycemia. Treat-
ment with metoprolol was stopped and angiotensin-convertingCASE PRESENTATION
enzyme inhibition was started. Shortly after, the patient devel-A 19-year-old female was admitted to the Steno Diabetes
oped an irritative cough that required cessation of this medica-Center 24 years ago because of poorly controlled type 1 diabetes,
tion. She was then given hydralazine, furosemide (as mentionedwhich had been diagnosed 6 years earlier. The patient was
earlier), and a calcium antagonist. The systolic blood pressuretreated with insulin twice daily and a diabetic diet. A simplex
rose (to 156/70 mm Hg), as did the albuminuria (2330 g/minretinopathy was diagnosed, and she had persistent albuminuria
or 3355 mg/24 h), while the GFR remained unchanged (60 mL/ranging between 500 and 650 g/min (720 and 936 mg/24 h).
min). She was given the angiotensin II type-1 receptor blockerHer blood pressure was 120/86 mm Hg and glomerular filtration
losartan when it became available 2 years ago; treatment in-rate (GFR: 51Cr-EDTA plasma clearance) was 119 mL/min. The
duced a significant decline in blood pressure, a decrease by one-urine sediment was normal and a urine culture was negative.
half of the albuminuria, and a decline in GFR to 48 mL/min.Because of the short duration of her diabetes, a renal biopsy
During the course of her renal disease, she became pregnant 19was performed; it showed diffuse diabetic glomerulopathy.
years ago and delivered a healthy child after an uncomplicatedDuring the following 3 years, the albuminuria increased pro-
pregnancy. Three years ago, screening demonstrated increasedgressively, reaching as high as 1815 g/min (2614 mg/24 h).
serum calcium and elevated parathyroid hormone (PTH). Sur-Her blood pressure rose to a final level of 136/105 mm Hg and
gical exploration revealed an adenoma (208 mg) in the parathy-GFR declined to 91 mL/min after 3 years of follow-up without
roid gland. Following surgery, her serum calcium became nor-any antihypertensive treatment. The rate of decline in GFR
mal. The patient still has a simplex retinopathy with normalaveraged 10.3 ml/min/year, mean blood pressure during the 3
visual acuity.years of observation was 126/90 mm Hg, and average albumin-
uria was 1021 g/min (1470 mg/24 h).
After three years of follow-up, treatment was initiated with
DISCUSSIONa selective beta-blocker, metoprolol, 200 mg daily; furosemide,
120 to 240 mg twice daily; and hydralazine, 25 (and then 50) Dr. Hans-Henrik Parving (Professor of Medicine,
mg twice daily. Apart from minor adjustments, this antihyper- Chief Physician, Steno Diabetes Center, Copenhagen, Den-
mark): The clinical syndrome termed diabetic nephropa-
thy is characterized by persistent albuminuria, blood
The Nephrology Forum is funded in part by grants from Amgen,
pressure elevation, a relentless decline in GFR, and aIncorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo-
rated; and Bristol-Myers Squibb Company. high risk of cardiovascular morbidity and mortality [1].
Diabetic nephropathy has become the leading cause
Key words: type 1 diabetes, type 2 diabetes, glycemic control, low-
(25% to 42% of patients) of end-stage renal diseaseprotein diet, lipid-lowering drugs, antihypertensive drugs, albuminuria,
hypertension, ESRD (ESRD) in Europe, Japan, and the United States [1].
Unfortunately, the proportion of patients with ESRD 2001 by the International Society of Nephrology
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suffering from diabetes, particularly type 2, is anticipated to elevated blood pressure exists in diabetes [20]. The
following abnormalities might contribute to the increasedto rise considerably because the number of diabetic pa-
tients in the world is expected to double within the next pressure susceptibility to vascular damage: generalized
vasodilation [21], impaired autoregulation of flow and10 years, onset of diabetes occurs earlier, and the individ-
ual diabetic patient lives longer and therefore is at pressure [22], nocturnal hypertension due to impaired
blood pressure lowering during the night [23], a greatergreater risk for developing late complications, including
diabetic nephropathy. In this presentation I will review rise in systemic blood pressure during exercise in long-
term diabetic patients compared with non-diabetics, andrisk factors and markers for the development and pro-
gression of diabetic nephropathy and will summarize the increased blood pressure variation over 24 hours (auto-
nomic neuropathy). Finally, an elevated blood pressurecurrent approaches to the prevention and treatment of
diabetic nephropathy. I will not, however, discuss the promotes progression in a variety of non-diabetic ne-
phropathies, as demonstrated in the MDRD study [24].treatment of ESRD with transplantation and dialysis.
A relentless but highly variable rate of decline in GFR Studies in various experimental animal models and
human disease suggest that proteinuria itself contributes(1 to 24 mL/min/year, median 12 mL/min/year) charac-
terizes patients with both type 1 and type 2 diabetes with to renal damage [25]. The worst prognosis has been shown
in type 1 diabetic patients with diabetic nephropathy andnephropathy [2–4]. Simultaneously, arterial blood pres-
sure and albuminuria progressively rise and the nephrotic nephrotic-range proteinuria. We have confirmed and ex-
tended this finding to the early stages of diabetic nephrop-syndrome ensues in 40% to 50% of patients. The patient
with type 1 diabetes predominantly develops diastolic athy [13]. Since then, other observational studies and
treatment trials have confirmed these findings [7, 15]. Inhypertension, whereas the type 2 diabetic patient typi-
cally manifests systolic hypertension. A close correlation our recent prospective study, we documented a threshold
effect of albuminuria equal to 600 mg/24 h [16]. Further-exists between the degree of diabetic glomerulopathy
and the level of GFR [5] and, even more important, in more, intervention that has ameliorated the progression
of diabetic and nondiabetic renal disease always has beenthe rate of decline in GFR [6]. Before advanced renal
replacement strategies became available and the advo- associated with a reduction in proteinuria, a so-called sur-
rogate end point. The MDRD study [24] and the Ramiprilcacy of early and aggressive antihypertensive therapy,
death occurred on average 5 to 10 years after the onset Efficacy in Nephropathy (REIN) study [26] have demon-
strated that proteinuria has a major role in the progres-of persistent proteinuria [4, 8-11]. End-stage renal disease
was the major cause of death in type 1 diabetic patients sive loss of GFR in non-diabetic glomerulopathies.
Originally, Nyberg et al demonstrated a correlationwith nephropathy; cardiovascular disease dominated in
proteinuric type 2 diabetic patients. between HbA1C and the rate of GFR decline in 18 patients
with type 1 diabetes who received aggressive antihyper-Increased arterial blood pressure is an early and fre-
quent phenomenon in diabetic nephropathy [12]. A close tensive treatment for 18 months [27]. This finding was
confirmed and extended in several studies dealing withcorrelation between blood pressure and the rate of de-
cline in GFR has been documented in patients with type 1 larger numbers of patients and longer observation inter-
vals [14, 15, 28, 29]. In our long-term prospective study,and type 2 diabetes [13-15]. Recently, we have confirmed
and extended this finding by measuring GFR, blood pres- we generated a two-hit model with mean blood pressure
and glycosylated HbA1C below and above the mediansure, albuminuria, HbA1C, and serum cholesterol every
year for 7 years (range, 3 to 14 years) in 301 consecutive values (102 mm Hg and 9.2%, respectively). The study
revealed a rate of decline in GFR of only 1.5 mL/min/type 1 diabetic patients with diabetic nephropathy re-
cruited during 1983 to 1997 [16]. The statistical analysis year in the lowest stratum compared to 6.1 mL/min/year
in the highest stratum (P 0.001) [16]. In contrast, mostrevealed no threshold for the adverse impact of systemic
blood pressure (BP) on the rate of decline in GFR. The of the studies in patients with type 2 diabetes and protein-
uria have failed to demonstrate any significant impactdamaging effect of systemic BP is probably due to trans-
mission of pressure downstream to the kidney. Intraglo- of glycemic control [3, 4]; the literature contains one
exception [30].merular hypertension has been documented in rats with
streptozotocin-induced diabetes [17] and possibly occurs In 1982, Moorhead et al hypothesized that hyperlipid-
emia promotes progression in chronic renal disease afterin human diabetes [18].
In 1982, Hostetter et al introduced the concept that the initiating event has damaged the glomerular capillary
wall, thereby allowing increased passage of lipids andincreased glomerular hydraulic pressure plays an impor-
tant role in the initiation and progression of experimental lipoproteins into the mesangium [31]. Several studies in
patients with type 1 and type 2 diabetes have shown adiabetic glomerulopathy [17]. At the same time, long-
term treatment trials with blood-pressure-lowering agents correlation between serum cholesterol concentration
and progression of diabetic nephropathy, at least in uni-documented the validity of this concept in humans [2, 19].
Evidence suggests that a special vascular vulnerability variate analyses [3, 4, 14, 15], although some studies have
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failed to demonstrate cholesterol as an independent risk
factor in multiple regression analysis. Our recent study
of 301 patients followed during seven years indicates
that elevated serum cholesterol acts as an independent
promoter of progression [16].
Dietary protein restriction retards the progression of
renal disease in virtually every experimental animal model
tested [32]. Surprisingly, the major observational studies
of patients with type 1 and type 2 diabetes and nephropa-
thy have failed to show an impact of dietary protein
intake on the rate of decline in GFR [3, 4, 7, 14, 27-29].
Christiansen suggested two decades ago that smoking
Fig. 1. Average change in the rate of decline in glomerular filtrationwas an independent risk factor for the initiation of dia- rate (GFR) during long-term angiotensin-converting-enzyme inhibition
betic glomerulopathy in patients with type 1 diabetes [33]. frequently combined with diuretics in patients with type 1 diabetes and
nephropathy, according to the I/D polymorphism of the angiotensin-This finding has been confirmed in numerous studies
converting-enzyme gene. Symbols are: () DD; () II  ID; P  0.01,[reviewed in 34]. In addition, some but not all studies DD vs. II  ID. (From [40].)
suggest that smoking can act as a progression promoter
in patients with type 1 and type 2 diabetes and protein-
uria [34]. More information is needed to draw a firm
conclusion. (Fig. 1). Four other studies have demonstrated that the
D allele is a risk factor for an accelerated course ofThe increased synthesis of angiotensin II plays an im-
portant role in the initiation and progression of diabetic diabetic nephropathy in patients with type 1 diabetes [28,
29, 41, 42], although in one of the studies the tendencynephropathy by affecting hemodynamic and non-hemo-
dynamic mechanisms [1]. Studies have shown that an towards a more rapid decline in renal function in the
DD genotype was not significant [28]. The potential con-insertion (I)/deletion (D) polymorphism of the angioten-
sin-converting enzyme (ACE) gene (ACE/ID) is associ- tribution from other relevant candidate genes remains
to be evaluated.ated with the level of circulating ACE and with an in-
creased risk of coronary heart disease in non-diabetic
Preventionpatients [35]. The plasma ACE level in patients with the
DD genotype is about twice that of patients with the Treatment strategies include: primary prevention, that
is, treatment modalities applied to any normalbuminuricII genotype, and patients with the ID genotype have
intermediate values. Yoshida et al followed 168 protein- diabetic patient at risk; secondary prevention, that is, treat-
ment modalities applied to a diabetic patient with a highuric patients with type 2 diabetes for 10 years and found
in an analysis of the clinical course of the three ACE risk (for example, microalbuminuria) for the development
of diabetic nephropathy; and finally, tertiary prevention,genotypes that the majority of the patients with the DD
genotype (95%) progressed to ESRD within 10 years that is, treatment of overt diabetic nephropathy aimed at
preventing or delaying the development of ESRD.[36]. Moreover, the DD genotype appears to increase
the mortality once dialysis is initiated. Two recent studies Primary prevention. Risk factors and markers for pro-
gression from normo- to micro- and macroalbuminuriahave confirmed that the D allele has a deleterious effect
on renal function in patients with type 2 diabetes [37, 38]. have been identified in patients with both type 1 and type
2 diabetes [43]. The two main treatment strategies thatFurthermore, more severe diabetic glomerulopathy le-
sions have been documented both during the develop- have been evaluated are blood-pressure–lowering drugs
and improved glycemic control. Three randomized pla-ment and the progression of renal disease in type 2 dia-
betic patients with the D allele [abstract; Solini et al, cebo-controlled trials in normotensive type 1 and type 2
diabetic patients with normalbuminuria have suggested aDiabetologia 43 (Suppl 1):A14, 2000]. Furthermore, mi-
croalbuminuric type 1 patients carrying the D allele have beneficial effect on the development of microalbuminuria
[44–46]. In contrast to these three studies, which werean increased progression of diabetic glomerulopathy, a
finding based on renal biopsies taken at baseline and carried out as placebo-controlled trials, the literature con-
tains three new studies comparing the effect of ACEafter 26 to 48 months of follow-up [39].
We showed an accelerated initial loss and a sustained inhibitors versus a long-acting dihydropyridine calcium
antagonist [47, 48], or  blockade [49] in hypertensiveloss of GFR during ACE inhibitor treatment of albumin-
uric type 1 patients homozygous for the DD polymor- type 2 diabetic patients with normoalbuminuria. All three
studies reported a similar beneficial renoprotective effectphism of the ACE gene [40]. The DD genotype indepen-
dently influenced the sustained rate of decline in GFR of blood pressure reduction with and without ACE inhi-
bition. Furthermore, the UKPDS study reported that byor, in other words, it acted as a progression promoter
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Fig. 2. Effects of intensive versus conventional blood glucose control on progression of nephropathy (from [50]).
six years a smaller proportion of patients in the group A small study in Japanese patients with type 2 diabetes
applied a similar design as the DCCT study and showedunder tight blood pressure control had developed micro-
albuminuria and a 29% reduction in risk (P  0.009), a beneficial effect on progression from normo- to micro-
and macroalbuminuria [52]. This study has been con-with a non-significant 39% reduction in the risk for pro-
teinuria (P  0.061) [49]. firmed and extended by the UKPDS data documenting
a progressive beneficial effect of intensive metabolic con-Wang and colleagues performed a meta-analysis of
seven randomized studies (N  266) comparing the ef- trol on the development of microalbuminuria and overt
proteinuria [53].fect of intensive versus conventional blood glucose con-
trol on the risk of progression to nephropathy in patients Secondary prevention. Several modifiable risk factors
and markers for progression from microalbuminuria towith type 1 diabetes and normoalbuminuria (80%) or
microalbuminuria (20%). Their results showed that the overt nephropathy (level of urinary albumin excretion
rate, HbA1C, blood pressure, serum cholesterol concen-risk of progression of nephropathy, defined as an incre-
ment in urinary albumin excretion rate, was decreased tration) have been identified in clinical trials and obser-
vational studies in patients with type 1 and type 2 diabe-with intensified treatment [odds ratio 0.34 (95% CI, 0.20
to 0.58); Fig. 2] [50]. Development of the categorical tes [54, 55]. A meta-analysis of 12 trials in 698 type 1
diabetic patients with microalbuminuria who were fol-variables micro- and macroalbuminuria was not ac-
counted for in this meta-analysis. In the Diabetes Control lowed for at least one year has revealed that ACE inhibi-
tors reduced the risk of progression to macroalbuminuriaand Complications Trial (DCCT), however, intensified
therapy in patients with type 1 diabetes reduced the by 62% compared to that of the placebo group [odds
ratio 0.38 (95% CI, 0.25 to 0.57)] [56]. Regression tooccurrence of microalbuminuria by 39% (95% CI, 21%
to 52%), and that of albuminuria by 54% (95% CI, 19% normoalbuminuria was three times greater than in the
patients receiving a placebo. At two years, the urinaryto 74%), when the two cohorts were analyzed together
[51]. Despite this reduction, 16% in the primary preven- albumin excretion rate was 50% lower in the patients
taking ACE inhibitors than in those receiving placebo.tion cohort and 26% in the secondary prevention cohort
developed microalbuminuria during the nine years of Furthermore, we showed that the beneficial effect of
ACE inhibitors on preventing progression from micro-intensified treatment. Furthermore, the trial documented
that the beneficial effect of intensified treatment does albuminuria to overt nephropathy is long lasting (eight
years) and, more importantly, it is associated with preser-not occur for at least three years. The DCCT trial clearly
documents that we need additional treatment modalities vation of normal GFR [57]. Recent data from a double-
blind randomized study lasting three years show thatto reduce or avoid the increasing burden of diabetic
nephropathy. long-acting dihydropyridine calcium antagonists are as
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Table 1. Progression of microalbuminuria to nephropathy in normo- and hypertensive diabetic patients with type 2 diabetes
N Observation Patients developing GFR
Author [reference] patients period years nephropathy %/yr mL/min/yr
Mogensen [59]a 59 9 2.4 —
Nelson et al [7]a 50 4 9.3 1
Ravid et al [55]ab 49 5 8.4 2
Gæde et al [60]b 80 4 5.8 3.2
Ahmad et al [61]ab 51 5 4.8 1
Parving et al (unpublished data) 86 5 7.0 —
Estacio et al [48]c 150 5 4.0 1
Gerstein et al [46]d 1140 4.5 4.5 —
a Normotensive/predominantly normotensive.
b Randomized controlled trials (placebo arm)
c Randomized controlled trial in predominantly hypertensive subjects receiving treatment with or without an ACE inhibitor
d Randomized controlled trial in hypertensive type 2 diabetic patients receiving an ACE inhibitor or long-acting dihydropyridine calcium antagonist
effective as ACE inhibitors in delaying the occurrence of diabetes and microalbuminuria [51, 64–67]. Statistical
analysis showed no significant impact on the distributionmacroalbuminuria in normotensive patients with type 1
diabetes who have persistent microalbuminuria [58]. A of the categorical variables normo-, micro-, and macro-
albuminuria (P  0.26) and on progression to overt ne-retrospective study by Mogensen suggested that the pro-
gression of microalbuminuria to overt nephropathy is phropathy (P  0.1). This disappointing result partly
might be due to the relatively short length of the follow-much slower in patients with type 2 compared to type 1
diabetes [59]. However, all prospective studies have up period, since the UKPDS study with 15 years of fol-
low-up documented a progressive beneficial effect withclearly documented a rate of progression between 4%
and 9% per year, equal to that in type 1 diabetic patients time on the development of proteinuria and a twofold
increase in plasma creatinine [53]. Furthermore, pancre-(Table 1) [7, 46, 48, 55, 60, 61]. Ravid et al originally
described the beneficial effect of ACE inhibition in nor- atic transplantation can reverse glomerulopathy in pa-
tients with type 1 diabetes and normo- (N 3) or micro-motensive microalbuminuric patients with type 2 diabe-
tes by demonstrating that only 12% of the patients in albuminuria (N  4), but reversal requires more than
five years of normoglycemia [68]. The renoprotectivethe ACE inhibitor group developed nephropathy, com-
pared to 42% in the placebo arm [55]. Later studies have effect of HMG CoA reductase inhibitors in patients with
type 1 or type 2 diabetes with micro- or macroalbumin-supported this finding [46]. Long-term studies (4 years)
in hypertensive patients with type 2 diabetes and micro- uria appears to be highly variable [69]. Recently, we
demonstrated that intensified multifactorial interventionalbuminuria have revealed a similar beneficial effect of
ACE inhibition and long-acting dihydropyridine calcium (pharmacologic therapy targeting hyperglycemia, hyper-
tension, dyslipidemia, and microalbuminuria) in patientsantagonists [48] and -blockers [49] on progression to
overt nephropathy. In contrast, a shorter term study (one with type 2 diabetes and microalbuminuria substantially
slows progression to nephropathy, retinopathy, and au-year) dealing with fewer patients reported a greater ben-
eficial effect of ACE inhibition versus a long-acting dihy- tonomic neuropathy [60].
Mogensen and colleagues published a consensus re-dropyridine calcium antagonist in hypertensive patients
with type 2 diabetes and microalbuminuria [62]. The role port on the detection, prevention, and treatment of dia-
betic nephropathy with special reference to microalbu-of short-term “dual blockade” of the renin-angiotensin
system in hypertensive, microalbuminuric patients with minuria [70]. They recommended that physicians try to
improve blood glucose control and treat with ACE inhib-type 2 diabetes also has been evaluated [63]. A combina-
tion of candesartan and lisinopril was even more effective itors. This recommendation is very cost-effective, mainly
because treatment for end-stage renal disease is so ex-than monotherapy for reducing blood pressure in such
patients, and the same trend was apparent for the reduc- pensive. From a pragmatic therapeutic standpoint, pre-
venting the progression of renal disease is most likelytion in urinary albumin excretion rate. A long-term (two
years) randomized double-blind, placebo-controlled trial to be achieved by a non-glycemic intervention such as
treatment with ACE inhibitors [56, 65].evaluating the renoprotective effects of angiotensin II
type 1 receptor blockade in hypertensive, microalbumi- Tertiary prevention. As I mentioned earlier, arterial
hypertension, albuminuria, and poor glycemic controlnuric patients with type 2 diabetes was terminated in
November 2000. are the most important risk factors for a progressive
decline in GFR in diabetic nephropathy, while dietaryTable 2 shows the five randomized studies comparing
the renal effect of intensified blood glucose control com- protein intake generally has been found to play a minor
or no role. However, a meta-analysis based on fivepared to conventional treatment in patients with type 1
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Table 2. Randomized studies comparing the renal effects of intensive (I) blood glucose control versus conventional (C) treatment in patients
with type 1 diabetes and microalbuminuria
Baseline Change in
number End of urinary albumin
Follow-up with micro- Normo- study micro- excretion rate
Study [Ref] years albuminuria albuminuria albuminuria Nephropathy %/year P
DCCT [51] 6.5 0.09
I 38 23 11 4 2.5
C 35 18 11 6 11
Stockholm study [64] 7 0.04
I 8 2 4 2 2.6
C 13 4 5 4 11.8
Microalbuminuria Collaborative
study, UK [65] 5 0.31
I 36 12 17 6
C 34 12 16 6
Steno study [66] 2 0.05
I 18 3 15 0 9
C 18 5 8 5 7
Oslo study [67] 2 NS
I 9 4 4 1 10.8
C 9 1 7 1 5.8
All studies
I 109a 44 51 13
C 109a 40 47 22
a Chi-square test, P  0.26 for distribution among the 3 groups, and P  0.15 for progression to nephropathy
studies in patients with type 1 diabetes and microalbu- that the reduction in albuminuria and blood pressure
induced by ACE inhibition is primarily caused by inter-minuria or proteinuria showed that a low-protein diet
(0.8 g/kg/day) significantly slowed the increase in uri- ference with the renin-angiotensin system. Furthermore,
the study suggests that losartan represents a valuablenary albumin excretion rate or the decline in GFR or
creatinine clearance (relative risk 0.56; 95% CI, 0.40 to new drug in the treatment of hypertension and protein-
uria in patients with type 1 diabetes and nephropathy.0.77) [71]. Flaws in design (short-term, non-randomized
cross-over study and self-control studies), methods (cre- Furthermore, we demonstrated that losartan can reduce
the abnormally elevated size-selective property of theatinine clearance), and insufficient adjustment for other
progression promoters, including antihypertensive treat- glomerular membrane in diabetic nephropathy, and that
this mechanism plays an important role in the antipro-ment with ACE inhibitors, have weakened the strength
of that conclusion [72]. Much more robust data are at teinuric effect of this compound [75]. Finally, in a dose
escalation study of losartan (50, 100, and 150 mg daily)hand in nondiabetic renal disease [71]. Randomized trial
data dealing with the impact of improved glycemic con- we demonstrated that the optimal dose of losartan is 100
mg daily for renoprotection and blood pressure reduc-trol on progression of diabetic nephropathy is restricted
to one study dealing with a limited number of patients tion in patients with type 1 diabetes and nephropathy
[abstract; Andersen et al, Diabetologia 43 (Suppl 1):[49].
Recently, De Jong et al stressed the importance of A261, 2000].
I should stress that the antiproteinuric effect of ACEutilization of careful measurement of urinary protein ex-
cretion when evaluating the renoprotective properties of inhibition in patients with diabetic nephropathy varies
considerably. Individual differences in the renin-angio-treatment; the analysis suggests that protein excretion
should be reduced as far as possible [73]. The antiprotein- tensin system can influence this variation. Two studies
suggest that patients with type 1 diabetes who have theuric effect of ACE inhibitors is well documented, but
ACE inhibitors reduce angiotensin II formation and in- II genotype of the ACE gene are particularly sensitive to
commonly advocated renoprotective treatment [76, 77].duce bradykinin accumulation. To dissect these effects, we
performed a double-blind, randomized, cross-over study Furthermore, the polymorphism of the ACE gene pre-
dicts therapeutic efficacy of ACE inhibition against pro-comparing an angiotensin II type 1 receptor antagonist,
losartan, with enalapril in patients with type 1 diabetes gression of nephropathy in patients with type 1 (and type
2) diabetes (abstract; Tomonaga et al, J Am Soc Nephroland nephropathy [74]. The study showed that losartan’s
ability to reduce albuminuria and blood pressure is simi- 8:120A, 1997) [40]. We recently demonstrated that the
individual antiproteinuric response to ACE inhibitionlar to the effect of ACE inhibitors. These results indicate
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positively correlated with the response to angiotensin sive benefit with time has been demonstrated on GFR
in non-diabetic renal diseases [86]. Remission of protein-II type 1 receptor blockade in diabetic as well as in
nondiabetic patients [78]. Thus, patients responding fa- uria for at least one year (proteinuria	 1 g/24 h) has been
described in patients with type 1 diabetes participating invorably to one class of antiproteinuric drugs also respond
favorably to other classes of available drugs. This finding the captopril collaborative study [87]. Eight of 108 pa-
tients experienced remission during long-term follow-upsupports a main role for individual patient factors in
responsiveness or resistance to antiproteinuric interven- [87]. We recently confirmed and extended these findings
in a long-term prospective observational study of 321tion.
From a clinical point of view, the ability to predict the patients with type 1 diabetes and nephropathy [abstract;
Hovind et al, Diabetologia 43(Suppl 1):A36, 2000]. Thelong-term effect of a recently initiated treatment modality,
for example, antihypertensive treatment, on renal func- cumulative incidence of nephrotic-range albuminuria
was 39%. Remission did not occur spontaneously but wastion would be of great value. In prospective studies deal-
ing with conventional antihypertensive treatment and induced in 28 of 126 patients (22%), 21 predominantly
treated with ACE inhibitors, and 7 with non-ACE inhibi-ACE inhibition, we found that the initial reduction in
albuminuria (surrogate end point) predicted a beneficial tors. The remission (defined by us as sustained album-
inuria 600 mg/24 h for at least one year), on average,long-term treatment effect on the rate of decline in GFR
(principal end point) in diabetic nephropathy [79]. These lasted 3.6 years (range, 1 to 18 years). The remission
group, not surprisingly, is characterized by slow progres-findings have been confirmed and extended [14], and
there have been similar findings in non-diabetic nephrop- sion of diabetic nephropathy and an improved cardiovas-
cular risk profile.athies [24, 80].
We found that initiation of antihypertensive treatment At the end of the 1980s, reports appeared that de-
scribed a beneficial effect of ACE inhibition on albumin-usually induces a decline in GFR that is 3 to 5 times
greater per unit of time than the decline observed during uria and rate of decline in GFR [88, 89]. In 1992, Bjo¨rck
and coworkers suggested that ACE inhibitors confer re-the sustained treatment period [81]. Whether this initial
phenomenon is reversible (hemodynamic) or irreversible noprotection—a beneficial effect on renal function and
structure above and beyond that expected from the blood-(structural damage) after prolonged antihypertensive
treatment has recently been the subject of investigation. pressure-lowering effect alone—in diabetic nephropathy
[90]. Their investigation was a prospective, open, ran-Our results render some support to the hypothesis that
in patients with type 1 diabetes and incipient or overt domized study lasting a mean of 2.2 years in patients
with type 1 diabetes. In 1993 The Captopril Collaborativenephropathy, the greater initial decline in GFR is due
to a functional (hemodynamic) effect of antihypertensive Study Group demonstrated a significant risk reduction
for doubling of serum creatinine concentrations in pa-treatment that does not attenuate over time, and the
subsequent slower decline reflects the beneficial effect tients with type 1 diabetes and nephropathy who received
captopril (48%; 95% CI, 16% to 69%) [91]. The placebo-on progression of nephropathy [56, 82, 83]. A similar
effect has been demonstrated in nondiabetic glomerulo- treated patients received conventional antihypertensive
treatment excluding calcium channel blockers. As I saidpathies [84]. In contrast to the findings in patients with
type 1 diabetes, our results suggest that the faster initial earlier, we recently reported that long-term treatment
(4 years) with an ACE inhibitor and long-acting dihydro-decline in GFR after initiating antihypertensive treat-
ment in hypertensive patients with type 2 diabetes and pyridine calcium antagonist has similar beneficial effects
on progression of diabetic nephropathy in hypertensivenephropathy is due to an irreversible effect [81].
In 1982, Mogensen described a beneficial effect of patients with type 1 diabetes [83].
Analysis of antihypertensive treatment with and with-long-term antihypertensive treatment in five hyperten-
sive men with type 1 diabetes and nephropathy [2]. Our out ACE inhibitors on the rate of decline in GFR in
hypertensive patients with type 2 diabetes and protein-prospective study initiated in 1976 has demonstrated that
early and aggressive antihypertensive treatment reduces uria is shown in Table 3. Except for one study [92], no
significant difference was found between the decline inalbuminuria and the rate of decline in GFR in young
men and women with type 1 diabetes and nephropathy GFR in patients over time with and without ACE inhibi-
tors (abstract; Walker et al, J Am Soc Nephrol 3:339,[19, 85]. Figure 3 illustrates the mean value for arterial
blood pressure, GFR, and albuminuria in nine patients 1992) [48, 93-95]. Against this background, two large
multinational, randomized placebo-controlled trials withreceiving long-term (9 years) treatment with metopro-
lol, furosemide, and hydralazine [85]. Note that the data angiotensin II type 1 receptor blockers are being carried
out in hypertensive patients with type 2 diabetes, protein-are consistent with a time-dependent renoprotective ef-
fect of antihypertensive treatment that in the long term uria, and elevated serum creatinine levels. These trials
will end in 2001 and 2002. Even though no specific reno-might lead to regression of the disease (GFR 	 1 mL/
min/year), at least in some patients. The same progres- protective effect of ACE inhibitors has been demon-
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Fig. 3. Average course of mean arterial blood
pressure, GFR, and albuminuria before ()
and during () long-term effective antihyper-
tensive treatment on nine patients with type
1 diabetes and nephropathy (from [85]).
Table 3. Angiotensin converting enzyme inhibition (ACEI) in patients with type 2 diabetes and proteinuria
Investigator Follow-up GFR
[reference] N Treatment years Proteinuria mL/min/year
Lebovitz [93] 46 ACEI vs. conv. 3 ↓ → 6.4 9.6
Bakris [92] 52 ACEI vs. CCB vs. BB 5 ↓↓ ↓↓ ↓ 1.0 1.4 3.3
Nielsen [94] 36 ACEI vs. BB 3 ↓↓ → 7.0 6.5
Estacio et al [48] 83 ACEI vs. CCB 5 ↓ ↓ 5.5 5.5
Fogari et al [95] 51 ACEI vs. CCB 2 ↓↓ ↓ 2.0 1.2
Abbreviations are for non-ACE inhibiting antihypertensive drugs; CCB, calcium channel blockers; BB,  blockers; conv, conventional.
strated in patients with type 2 diabetes, it should be ment on progression of diabetic nephropathy was re-
ported [2, 19]. The renal prognosis in patients with typestressed that a beneficial effect of antihypertensive treat-
ment has been documented in all trials dealing with type 2 diabetes and proteinuria is similar to that in patients
with type 1 [4, 11]. Recently we extended the follow-up2 diabetic patients with nephropathy.
of our 45 patients with diabetic nephropathy [96] until
Prognosis death or for at least 16 years (median 16 years; range,
4 to 21 years) [97]. The median survival time in our studyOn average, death occurs five to seven years after the
start of persistent proteinuria [8–10]. This information exceeded 16 years (Fig. 4) and serum creatinine was 116
mol/L (74 to 311 mol/L; 1.3 mg/dL; range 0.8 to 3.5is based on the three studies reflecting the natural course
of diabetic nephropathy as observed before the benefi- mg/dL) in the 23 surviving patients. These results were
confirmed in another long-term observational follow-upcial effect of early and aggressive antihypertensive treat-
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QUESTIONS AND ANSWERS
Dr. John T. Harrington (Dean, Tufts University
School of Medicine, Boston, Massachusetts, USA): One
of the major problems in the United States is the increas-
ing obesity of the American population. It is predicted
that in the next decade we will see a 50% increase in
the number of overt diabetics in the US. Presumably
there will be many more at risk of diabetic nephropathy
even if they are treated in the aggressive way you have
proposed. How can we solve that problem?
Dr. Parving: You can reduce the problem by closing
down all the McDonalds and all the other fast food shops,
because overeating is the major issue. According to the
Fig. 4. Cumulative death rate during the natural history of diabetic World Health Organization, it is not only a problem in
nephropathy in patients with type 1 diabetes (, N  112, Kussman et
the US but a major concern around the world. We haveal [9]); 
, N  45, Knowles [10]; , N  360, Andersen et al [8])
compared with patients who received effective antihypertensive treat- an “epidemic” of diabetes due to obesity and reduced
ment (, N  45, Parving et al [96, 97]). physical exercise. The following recommendations will
reduce the problem: eat fewer calories, eat less fat, and
perform regular physical activity, such as half an hour
walking every day, preferably long enough to work upstudy showing a median survival time of 13.9 years (95%
a sweat.CI, 11.8 to 17.2 years) in 263 patients with type 1 diabetes
Dr. Harrington: I have been fascinated over the lastand nephropathy [98]. The study also showed that only
few years by the increasing data on ACE polymorphism35% of deaths were due to ESRD (that is, dying with
and the adverse effect of the DD genotype. Should weserum creatinine concentration above 500 mol/L or 5.7
routinely determine ACE polymorphism in all new dia-mg/dL).
betics, or should we simply treat all patients as you pro-The first information on prognosis in type 1 diabetes
posed?based on a randomized, double-blind, placebo-control-
Dr. Parving: You should treat diabetic patients earlyled antihypertensive treatment trial was presented by the
and aggressively with antihypertensive agents the way ICollaborative Study Group of Angiotensin-Converting-
proposed. At Steno Diabetes Center, we determine theEnzyme Inhibition with Captopril in diabetic nephropa-
insertion/deletion ACE polymorphism in albuminuricthy [91]. The mean duration of the study was 2.7 years,
patients with type 1 and type 2 diabetes. We are doingand risk reduction for the occurrence of death or progres-
so to improve the characterization of the individual risksion to dialysis or transplantation was 61% (95% CI,
profile, and we hope that we will have better opportuni-26% to 80%, P  0.002) in the subgroup of 102 patients
ties for creating more effective individualized treatmentwith a baseline serum creatinine concentration 133
in the future.mol/L (1.5 mg/dL), and 46% (P  0.14) in the 307
Dr. Julie Lewis (Professor of Medicine, Division ofpatients with serum creatinine concentration at baseline
Nephrology, Vanderbilt University Medical Center, Nash-133 mol/L (1.5 mg/dL) when treated with captopril
ville, Tennessee, USA): You concluded that we dramati-compared with placebo. An economic analysis of the use
cally change the life expectancy and quality of life of theseof captopril in diabetic nephropathy in the United States
patients with antihypertensive therapy. When should weshowed that ACE inhibitors provide significant savings
begin this therapy? I am frequently referred young peo-in health care costs [99].
ple, for example, women with type 1 diabetes, whose blood
Conclusion pressure is 130/80 mm Hg, but when I look at their charts,
five or six years previously their blood pressure wasThere appear to be no substantial differences between
110/60 mm Hg or 90/50 mm Hg. Should we be targetingpatients with type 2 and those with type 1 diabetes with
these young diabetics for much earlier therapy, particu-respect to the initiation, progression, and treatment of
larly since it seems to be of such great benefit to themdiabetic nephropathy. What is more important is that
in the long run?modifiable risk factors have been identified, including ele-
Dr. Parving: That is a very important question. Threevated blood pressure and proteinuria, for both initiation
double-blind randomized studies comparing ACE inhib-and progression of diabetic nephropathy. The natural
itors with placebo have tried to answer the question incourse of diabetic nephropathy can be favorably altered
relation to the risk of developing microalbuminuria inby antihypertensive drug therapy and tight glycemic con-
trol. normotensive or hypertensive patients with type 1 [44]
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or type 2 diabetes [45, 46]. The reported relative risk Increased compliance with a lifelong treatment in an
asymptomatic patient requires reinforcement all the time.reduction ranged from 9% to 13%, which was significant
in one study [45], and tended to be significant in the Dr. Edmund J. Lewis (Professor of Medicine, Rush
Medical College, Chicago, Illinois, USA): The issue ofremaining two. The Heart Outcomes Prevention Evalua-
tion (HOPE) investigators [46] suggest that all patients remission in patients who have nephrotic-range protein-
uria is important because that is the worst case scenario,with type 2 diabetes be treated with ACE inhibitors
irrespective of the blood pressure level because a bene- as Kussmann pointed out [9]. What is your opinion in
terms of blood pressure goals and ACE inhibition?ficial effect on death and all cardiovascular end points
was demonstrated in the study. A similar trial is not Dr. Parving: My blood pressure goal is: the lower the
better, apart from orthostatic hypotension. I say thisavailable in type 1 diabetic patients. Finally, I agree with
your suggestion that a significant increase in blood pres- because of studies that have shown improved quality
of life with lower blood pressure values, lack of bloodsure might qualify for initiation of antihypertensive treat-
ment even if the usual level of start of antihypertensive pressure threshold, and no J-shape curve. We recom-
mended ACE inhibitors combined with diuretics, withtreatment is not present (135/85 mm Hg).
Dr. Geoffrey Boner (Director, Institute of Nephrol- the addition of a beta-blocker and/or a calcium channel
blocker. If, as discussed earlier, the beneficial effect ofogy, Rabin Medical Centre, Petach Tikva, Israel): I would
like to comment on the combined use of ACE inhibitors dual blockade of the renin-angiotensin system is con-
firmed, then an angiotensin II receptor antagonist shouldwith angiotensin receptor blockers. My collaborator Dr.
van Dijk, who has been following a larger cohort of be on board, which would block the chymase pathway
and eliminate the ACE escape phenomenon. The angio-diabetic patients, put together a group of proteinuric
diabetics who had not received ACE inhibitors. He gave tensin II receptor antagonist is unique, as it has a side
effect profile equal to that of placebo. In brief, if youthem ACE inhibitors and if they did not respond, he
added an angiotensin receptor blocker. The combined strive to obtain remission of nephrotic-range proteinuria,
then go for “the full Monty.”treatment reduced blood pressure but produced no
change in proteinuria and no change in the decline in Dr. Harrington: Let me offer a direct answer. My
goal in all patients is to reach a blood pressure of 125/75GFR (unpublished data). This was an open study in a
selected group. mm Hg. That is the level suggested by the Modification
of Diet in Renal Disease (MDRD) study. Although theI also would like to ask a question. You mentioned
work by Dr. Gaede showing that intensive multifactorial MDRD study did not show any effect of a low-protein
diet, it did show a beneficial effect of lowered bloodtreatment can improve the lot of diabetic patients, pre-
vent the development of diabetic nephropathy, and even pressure in patients with renal disease [24].
Dr. GianCarlo Viberti (Professor of Diabetes andproduce remissions [60]. You also stated that in your
country most patients are treated by the family prac- Metabolic Medicine, Guy’s, King’s and St. Thomas School
of Medicine, King’s College, London, UK): When I looktitioner. The evidence is in, so what should we do now?
Most of these patients are referred to nephrologists or at your data on remission and regression, I see that even
for the best blood pressure control, which in your seriesother specialists very late in the course of their disease.
How can we reach these patients earlier? was a mean blood pressure of 90 mm Hg, the responders
are at most 40%. This finding suggests that for an averageDr. Parving: The candesartan and lisinopril micro-
albuminuria (CALM) study documented a beneficial ef- blood pressure, the percentage of responders is consis-
tently lower, leaving substantial room for further improve-fect on blood pressure and urinary albumin excretion
rate by dual blockade of the renin-angiotensin system ment. Perhaps progression responds to multiple factors.
Have you had the opportunity to dissect out the factorsin microalbuminuric hypertensive patients with type 2
diabetes [63]. We recently documented a renoprotective that distinguish the responders from the non-respond-
ers? In other words, are the non-responders whose meaneffect of dual blockade of the renin-angiotensin system
in type 2 diabetic patients treated with combination ther- blood pressure fell to 90 mm Hg the patients with the
highest HbA1C or the highest cholesterol, for example?apy, including the maximally recommended dose of an
ACE inhibitor (unpublished data). The study was carried Besides blood pressure, what other parameters contrib-
ute to our failure or success?out as a double-blind, randomized crossover trial.
Referring to your crucial point dealing with how we Dr. Parving: First of all, I would like to stress that the
finding of remission and regression in a sizable fraction ofimplement trial data, I am not able to give you a straight
answer. It is important that we educate general prac- our diabetic nephropathy patients is a major success.
Twenty years ago, you would not have believed me be-titioners and our colleagues at the hospitals and that we
reinforce the information over and over again. Further- cause in those days we did not know that we could reduce
proteinuria so much in diabetic nephropathy. Further-more, structured education of our patients has been doc-
umented to increase compliance and improve prognosis. more, if I had told you that it is possible to obtain a rate
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of decline in GFR of only 1 mL/min/year, your response doing anything more. If you have a good suggestion for
what we should do, I would be happy to take it with mewould have been, how did you do that?
On the other hand, your questions are extremely im- back to Denmark.
Dr. Gilbert: We know that silent ischemia is commonportant. In our analysis of 301 consecutive type 1 diabetic
patients suffering from diabetic nephropathy, we found in diabetic patients and that bypass surgery favorably
affects prognosis in certain subgroups. My question is,that several non-hemodynamic factors acted as progres-
sion promoters during a follow-up period of 7 years: should this woman have an exercise stress test and, if
so, when?albuminuria, glycemic control, and serum cholesterol
[16]. Furthermore, the insertion/deletion ACE polymor- Dr. Parving: You are touching on a very important
issue. Silent myocardial infarction (MI) occurs in approx-phism might play a role as a risk factor for losing filtration
power. In other words, these data suggest that a higher imately 30% of diabetic patients. They are referred to
the hospital in heart failure or they die suddenly at home.response rate can be obtained if multifactorial interven-
tion is applied, as we recently have documented in a study Unfortunately, at our hospital we do not have a specific
policy for evaluating patients with nephropathy for coro-of hypertensive type 2 diabetic patients with persistent
microalbuminuria [60]. nary artery disease. Our standard screening procedure
is a resting 12-lead electrocardiogram (EKG). What isDr. Viberti: Can you substantiate what you just told
me by dissecting out the baseline data that you have? the recommended policy in Australia for such high-risk
patients?Are non-blood-pressure-related factors different in those
people who responded than in those who did not re- Dr. Gilbert: We do not have a policy. However, I
can say from my experience that on numerous occasionsspond?
Dr. Parving: I can give you an answer in relation to I have arranged for an exercise EKG in patients whose
profile suggests high cardiovascular risk. In these pa-remission of nephrotic-range proteinuria. The baseline
data in patients who had a remission versus those who tients, painless, exercise-induced ischemia seems to be
relatively common. In several cases, the cardiologistsdid not were completely alike. These factors included
duration of diabetes, level of albuminuria, HbA1c, arte- have been sufficiently concerned to arrange for bypass
surgery on a semi-urgent basis. I raise the issue of investi-rial blood pressure, and total cholesterol. We could not
predict at baseline which patients were going to have a gation for silent ischemia in this woman in the setting
of her high risk.remission and who would not, but of course more careful
analysis might show something. The only factor that pre- Dr. Parving: I completely agree with you, and I would
be happy to bring the message back home to Steno:dicted remission of nephrotic syndrome was that females
have a higher chance of remission than do males. early detection of silent ischemia is mandatory in high-
risk populations.Dr. Richard Gilbert (Associate Professor, University
of Melbourne, St. Vincent’s Hospital, Fitzroy, Victoria, Dr. Harrington: Another new technique for de-
tecting arteriosclerosis is beginning to be used in theAustralia): This woman is now 43 years of age. Although
you are considerably slowing the progression of her ne- United States. The technique is magnetic resonance im-
aging of calcification in the coronary arteries, which hasphropathy, her renal function continues to decline. In
addition, she is hypertensive, she has autonomic neurop- a high correlation with coronary atherosclerosis and
myocardial infarction. I strongly suspect that the patientathy and, with the loss of the protective effect of female
gender in diabetes, she is at high risk of death from presented would have such calcification. Still, we have
no way of knowing from that test alone what we shouldcardiovascular causes in the next few years. Do you have
any plans for treating her cardiovascular disease apart do next. Some of the Boston teaching hospitals are adver-
tising this test literally for anyone willing to pay $250 tofrom the usual housekeeping measures such as choles-
terol lowering? $500! The test is not covered by any insurance program,
but you could all find out whether you have calciumDr. Parving: You are completely right in stating that
a patient with type 1 diabetes and proteinuria has a in your coronary arteries, then have more red wine to
“correct” that problem during the next weekend!very high risk of cardiovascular disease. Actually, the
observational studies made two decades ago by Knut Dr. Parving: Thank you, this information is new to
me. Maybe I could add that normotensive, normoalbum-Borch-Johnsen at the Steno told us that the risk of car-
diovascular death increased 40-fold in patients with pro- inuric type 2 diabetic patients have a prevalence of left-
ventricular hypertrophy of 31%, as demonstrated in ateinuria [100]. We are trying to improve glycemic control
but we are not doing a good job, as her HbA1C level is consecutive series of more than 348 patients at our insti-
tution [abstract; Knudsen et al, Diabetologia 42(Sup-9%. She is receiving cholesterol-lowering treatment with
statins. She also receives low-dose aspirin and of course pl):A60, 1999]. All patients were investigated by Asako
Sato. Furthermore, we demonstrated by using positiveshe receives blood-pressure-lowering agents. She does
not smoke, she is very fit, and I do not think that we are emission tomography scans that such patients had an
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increased cardiac production of angiotensin II (unpub- or borderline elevated blood pressure, and you add a
dihydropyridine calcium channel blocker, and the pa-lished data). Increased angiotensin II formation probably
is harmful to the heart among other organs because it tient’s albuminuria increases. What are you going to do?
Dr. Parving: Your points are well taken. Indeed, doc-creates fibrosis, a commonly recognized abnormality in
the diabetic heart. These studies show increased cardiac tors are worried by the increase in albuminuria docu-
mented in the past in trials using short-acting calciumrisk in an apparently “low-risk” diabetic group.
Dr. Itamar Raz (Head, Diabetes Unit, Hadassah Hos- channel blockers. Even long-acting calcium channel block-
ers don’t always reduce albuminuria initially as do ACEpital, Jerusalem, Israel): Regarding the need for cardio-
vascular intervention in your patient, I have a question inhibitors and angiotensin II receptor antagonists. How-
ever, several long-term (1 year) double-blind random-based on a study we are conducting on 78 patients with
type 2 diabetes and overt nephropathy. In this study we ized studies, both in type 1 and type 2 diabetic patients
with microalbuminuria and overt nephropathy, havehave 15 patients who have serum creatinine levels ranging
from 2.3 to 4.6 mg/dL, and all of them have severe heart documented a long-term renoprotective effect of calcium
channel blockers equal to that of ACE inhibitors [83].disease. Because I believe that not performing cardiac
catheterization in these patients is of great importance To control blood pressure in diabetic patients, we fre-
quently need to administer two or even three agents. Ain keeping them from progressing to end-stage renal
disease, I try to avoid putting patients through catheter- combination of an ACE inhibitor or an angiotensin II
receptor antagonist with a calcium channel blocker seemsization, percutaneous coronary angioplasty, and coro-
nary artery bypass. After nearly four years of follow-up, to be a good solution. However, most of our patients also
need a diuretic to cope with sodium and fluid retentionnone of the patients participating in the study developed
end-stage renal disease due to such interventions, nor common in diabetic patients with albuminuria.
Dr. Julie Lewis: I am very interested in sudden deathdid any of the patients expire because of heart disease.
These data have not yet been corroborated by a scien- due to autonomic neuropathy. We do cardiac catheter-
ization before transplantation, so I have a subset of pa-tifically rigorous analysis of the evidence at hand. The
literature indicates that type 2 diabetic patients with tients whom I know have clean coronary arteries and
normal ejection fractions. Yet some of these patientsproven coronary artery disease should be treated aggres-
sively using coronary artery bypass or, less favorably, by died suddenly at home. Have you studied sudden death
in your patients?coronary angioplasty. However, diabetic patients with
renal failure who have this procedure are at great risk of Dr. Parving: Autonomic neuropathy, that is, unop-
posed sympathetic activity, is a well-known complicationdeveloping end-stage renal disease. On the other hand,
catheterization and coronary artery bypass only occa- that can be diagnosed easily by measuring the so-called
beat-to-beat variation on ECG when the subject is breath-sionally demonstrate improvement of prognosis in dia-
betic patients. ing deeply. The prevalence rises with duration of diabetes
and many other complications. The prevalence of impairedMy question is: Is further investigation needed in this
woman, who has had diabetes for 25 years and now or abolished beat-to-beat variation and/or prolonged QT
interval in diabetic nephropathy is approximately 50%has overt nephropathy, despite her normal exercise test
results? Second, is the course of large vessel disease in [101]. Recently, we demonstrated that multifactorial in-
tervention aimed at improving glycemic control, blooddiabetes similar to that of small vessel disease, namely,
does a patient who does not exhibit atherosclerosis after pressure levels, and hyperlipidemia can improve auto-
nomic neuropathy in type 2 diabetic patients with micro-25 years of diabetes have a better chance of not devel-
oping atherosclerosis in the future? albuminuria [60]. Furthermore, treatment with beta-
blockers reduces the risk of arrhythmia and/or suddenDr. Parving: I cannot give you the answers because
I do not have the data. But the information that you and death and confers a beneficial effect on heart failure, a
frequent condition in patients with diabetic nephropathy.Dr. Gilbert have presented implies that I have to tell
my colleagues that we need to have a different attitude Dr. Kasper Rossing (Research Fellow, Steno Diabetes
Center, Copenhagen, Denmark): What are the newestin evaluating our high-risk patients for coronary heart
disease. I am very pleased to be pointed in that direction. strategies for treatment of diabetic nephropathy?
Dr. Parving: In brief, potential treatment modalitiesDr. Mark Cooper (Professor, Department of Medicine,
University of Melbourne, Victoria, Australia): You al- for preventing and treating diabetic nephropathy include
advanced glycosylation end product inhibition, proteinways have emphasized monitoring albuminuria and that
a reduction in albuminuria reflects improvement in renal kinase C inhibition, growth hormone receptor antago-
nism, antioxidant therapy, glycosaminoglycan therapy,function. Obviously with ACE inhibitors and maybe beta-
blockers, it seems to be true. What is your view about cyclo-oxygenase-2 inhibition, thiazolidinedione therapy,
and vasopressin receptor blockade. Most of the agentscalcium channel blockers, such as dihydropyridines? For
example, say you have a patient with diabetes and normal have only been investigated in vitro and in animal experi-
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